Maternal Pertussis Vaccine for Newborn Protection Market Report – Research, Industry Analysis Reports and Market Demands

Global Maternal Pertussis Vaccine for Newborn Protection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Acellular Pertussis Vaccine
- 1.3.3 Whole-cell Pertussis Vaccine
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital
- 1.4.3 Centers for Disease Control and Prevention
- 1.4.4 Others
1.5 Global Maternal Pertussis Vaccine for Newborn Protection Market Size & Forecast
- 1.5.1 Global Maternal Pertussis Vaccine for Newborn Protection Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Quantity (2021-2032)
- 1.5.3 Global Maternal Pertussis Vaccine for Newborn Protection Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Maternal Pertussis Vaccine for Newborn Protection by Manufacturer

3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Manufacturer (2021-2026)
3.2 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Manufacturer (2021-2026)
3.3 Global Maternal Pertussis Vaccine for Newborn Protection Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Maternal Pertussis Vaccine for Newborn Protection by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Maternal Pertussis Vaccine for Newborn Protection Manufacturer Market Share in 2025
- 3.4.3 Top 6 Maternal Pertussis Vaccine for Newborn Protection Manufacturer Market Share in 2025
3.5 Maternal Pertussis Vaccine for Newborn Protection Market: Overall Company Footprint Analysis
- 3.5.1 Maternal Pertussis Vaccine for Newborn Protection Market: Region Footprint
- 3.5.2 Maternal Pertussis Vaccine for Newborn Protection Market: Company Product Type Footprint
- 3.5.3 Maternal Pertussis Vaccine for Newborn Protection Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Maternal Pertussis Vaccine for Newborn Protection Market Size by Region
- 4.1.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Region (2021-2032)
- 4.1.2 Global Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Region (2021-2032)
- 4.1.3 Global Maternal Pertussis Vaccine for Newborn Protection Average Price by Region (2021-2032)
4.2 North America Maternal Pertussis Vaccine for Newborn Protection Consumption Value (2021-2032)
4.3 Europe Maternal Pertussis Vaccine for Newborn Protection Consumption Value (2021-2032)
4.4 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Consumption Value (2021-2032)
4.5 South America Maternal Pertussis Vaccine for Newborn Protection Consumption Value (2021-2032)
4.6 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Type (2021-2032)
5.2 Global Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Type (2021-2032)
5.3 Global Maternal Pertussis Vaccine for Newborn Protection Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Application (2021-2032)
6.2 Global Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Application (2021-2032)
6.3 Global Maternal Pertussis Vaccine for Newborn Protection Average Price by Application (2021-2032)

7 North America

7.1 North America Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Type (2021-2032)
7.2 North America Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Application (2021-2032)
7.3 North America Maternal Pertussis Vaccine for Newborn Protection Market Size by Country
- 7.3.1 North America Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Country (2021-2032)
- 7.3.2 North America Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Type (2021-2032)
8.2 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Application (2021-2032)
8.3 Europe Maternal Pertussis Vaccine for Newborn Protection Market Size by Country
- 8.3.1 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Market Size by Region
- 9.3.1 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Type (2021-2032)
10.2 South America Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Application (2021-2032)
10.3 South America Maternal Pertussis Vaccine for Newborn Protection Market Size by Country
- 10.3.1 South America Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Country (2021-2032)
- 10.3.2 South America Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Market Size by Country
- 11.3.1 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Maternal Pertussis Vaccine for Newborn Protection Market Drivers
12.2 Maternal Pertussis Vaccine for Newborn Protection Market Restraints
12.3 Maternal Pertussis Vaccine for Newborn Protection Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Maternal Pertussis Vaccine for Newborn Protection and Key Manufacturers
13.2 Manufacturing Costs Percentage of Maternal Pertussis Vaccine for Newborn Protection
13.3 Maternal Pertussis Vaccine for Newborn Protection Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Maternal Pertussis Vaccine for Newborn Protection Typical Distributors
14.3 Maternal Pertussis Vaccine for Newborn Protection Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Maternal Pertussis Vaccine for Newborn Protection market size was valued at US$ 6136 million in 2025 and is forecast to a readjusted size of US$ 7744 million by 2032 with a CAGR of 3.4% during review period.
In 2024, global Maternal Pertussis Vaccine for Newborn Protection production reached approximately 350 million doses, with an average global market price of around US$ 16 per square meter. Maternal Pertussis Vaccine for Newborn Protection is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. In this report, we cover all the pertussis-containing vaccines. Gross margin for the Maternal Pertussis Vaccine for Newborn Protection in general shows that manufacturers often achieve roughly 50–70% gross margins, depending on the producer, country, and contract.
The global Maternal Pertussis Vaccine for Newborn Protection market continues to grow steadily, driven by rising awareness of whooping cough, expanding childhood immunization programs, and increasing recommendations for adolescent and adult Tdap boosters. Demand is especially strong in developing regions where pertussis remains endemic, while mature markets are supported by routine pregnancy immunization and periodic booster campaigns. Major manufacturers focus on improving vaccine safety, supply stability, and combination formulations such as DTaP, which simplify national immunization schedules. Although pricing and procurement are heavily influenced by government tenders and international organizations, overall market growth is supported by public-health initiatives, technological advances in acellular vaccine production, and efforts to increase global vaccination coverage. The Maternal Pertussis Vaccine for Newborn Protection industrial chain is a complex, highly regulated, and technology-intensive ecosystem that spans from upstream antigen research to downstream global immunization delivery. It is characterized by significant barriers to entry, stringent quality control, and a delicate balance between public health objectives and commercial viability. The chain begins with basic and applied research into Bordetella pertussis antigens. This includes the identification, genetic sequencing, and optimization of key immunogenic components such as Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbrial proteins (FIM). For acellular vaccines (aP), the upstream segment involves mastering large-scale fermentation, toxin purification, and detoxification (converting PT to Toxoid) processes. This stage also encompasses the production of specialized adjuvants (e.g., aluminum salts) and critical raw materials for cell culture media and buffers. Innovation here focuses on improving antigen yield, purity, stability, and developing novel adjuvant systems to enhance and prolong immunity. The demand for Maternal Pertussis Vaccine for Newborn Protections is driven by the persistent prevalence of whooping cough, growing awareness of immunization benefits, and expanding vaccination programs for infants, adolescents, and adults. Rising adoption of Tdap boosters during pregnancy and among healthcare workers further fuels market growth. Opportunities exist in developing countries where vaccination coverage is still limited, as well as in urban areas of developed nations with increasing focus on adult immunization and combination vaccines like DTaP to simplify schedules. Additionally, technological innovations in acellular vaccine production, improvements in cold-chain logistics, and government-supported public health initiatives create potential for new market entrants and partnerships. Manufacturers that can offer safe, effective, and easily deployable vaccines, along with reliable supply chains, are well-positioned to capture market share in both emerging and mature markets.
This report is a detailed and comprehensive analysis for global Maternal Pertussis Vaccine for Newborn Protection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Maternal Pertussis Vaccine for Newborn Protection market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Maternal Pertussis Vaccine for Newborn Protection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Maternal Pertussis Vaccine for Newborn Protection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Maternal Pertussis Vaccine for Newborn Protection market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Maternal Pertussis Vaccine for Newborn Protection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Maternal Pertussis Vaccine for Newborn Protection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products, Minhai Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Maternal Pertussis Vaccine for Newborn Protection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
DTaP
Tdap
DTwP
Market segment by Composition
Acellular Vaccines
Whole-cell Vaccines
Market segment by User
Below 12 Months
Above 12 Months
Market segment by Application
Hospital
Clinic
Major players covered
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Maternal Pertussis Vaccine for Newborn Protection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Maternal Pertussis Vaccine for Newborn Protection, with price, sales quantity, revenue, and global market share of Maternal Pertussis Vaccine for Newborn Protection from 2021 to 2026.
Chapter 3, the Maternal Pertussis Vaccine for Newborn Protection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Maternal Pertussis Vaccine for Newborn Protection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Maternal Pertussis Vaccine for Newborn Protection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Maternal Pertussis Vaccine for Newborn Protection.
Chapter 14 and 15, to describe Maternal Pertussis Vaccine for Newborn Protection sales channel, distributors, customers, research findings and conclusion.

Buy now